Source link : https://www.newshealth.biz/health-news/novel-combo-with-engineered-nk-cells-in-early-trial-for-breast-cancer/
At the San Antonio Breast Cancer Symposium, Margaret Gatti-Mays, MD, MPH, of the Ohio State University in Columbus, discussed the ongoing phase Ib/II DiG NKs trial, which is assessing gemcitabine, transforming growth factor beta (TGF-β)-imprinted natural killer (NK) cells, with or without the GD2-binding antibody naxitamab (Danyelza) in metastatic GD2-expressing breast cancer. In this exclusive […]
Author : News Health
Publish date : 2025-01-10 18:25:42
Copyright for syndicated content belongs to the linked Source.